Skip to content
NeuroTechGuide

Open-label trial tests non-invasive vagus nerve stimulation for long COVID

A remote, DTRA-funded study of 541 adults compared electroCore's handheld nerve stimulator, a sound-based therapy, both, or monitoring alone. All active arms improved, but none beat the others.

A randomized trial of non-invasive vagus nerve stimulation for long COVID was published online in Neuromodulation and announced by electroCore on November 12. The remote study, funded by the US Defense Threat Reduction Agency, enrolled 541 adults with symptoms lasting at least three months; 250 met the criteria for final analysis. For four weeks, participants used electroCore’s neck-worn stimulator, a headphone-based sound therapy from Sonocea, both, or monitoring alone. Depression scores fell about a third in each active arm versus about 2% with monitoring, and the active arms did not differ from each other.

The trial was open-label with no sham control, relied on self-reported outcomes, and did not correct for multiple comparisons, so the authors call the results hypothesis-generating. The lead author is electroCore’s co-founder. Neither therapy is FDA-cleared for long COVID.

Learn more: electroCore

Share:XLinkedInBlueskyEmail

More news